Lu B, Yu H, Zwartbol M, Ruifrok WP, van Gilst WH, de Boer RA, Silljé HHW. Identification of hypertrophy-and heart failureassociated genes by combining in vitro and in vivo models. Physiol Genomics 44: 443-454, 2012. First published February 21, 2012 doi:10.1152/physiolgenomics.00148.2011.-Heart failure (HF) is a complex disease involving multiple changes including cardiomyocyte hypertrophy (growth). Here we performed a set of screens in different HF and hypertrophy models to identify differentially expressed genes associated with HF and/or hypertrophy. Hypertensive Ren2 rats and animals with postmyocardial infarction (post-MI) HF were used as in vivo HF models, and neonatal rat cardiomyocytes treated with hypertrophy inducing hormones phenylephrine, endothelin-1, and isoproterenol were used as in vitro models. This combined approach revealed a robust set of genes that were differentially expressed both in vitro and in vivo. This included known genes like NPPA (ANP) and FHL1, but also novel genes not previously associated with hypertrophy/HF. Among these are PTGIS, AKIP1, and Dhrs7c, which could constitute interesting targets for further investigations. We also identified a number of in vivo specific genes and these appeared to be enriched for fibrosis, wounding, and stress responses. Therefore a number of novel genes within this in vivo specific list could be related to fibroblasts or other noncardiomyocytes present in the heart. We also observed strong differences between the two HF rat models. For example KCNE1 was strongly upregulated in Ren2, but not in post-MI HF rats, suggesting possible etiology-specific differences. Moreover, Gene Ontology analysis revealed that genes involved in fatty acid oxidation were specifically down regulated in the post-MI group only. Together these results show that combining multiple models, both in vivo and in vitro, can provide a robust set of hypertrophy/HF-associated genes. Moreover it provides insight in the differences between the different etiology models and neurohormonal effects. gene expression; gene array; cardiomyocyte; fetal gene program HEART FAILURE (HF) is often the end-result of a number of cardiovascular diseases, including myocardial infarction, hypertension, and valve abnormalities. To maintain sufficient cardiac output under these conditions the heart adapts to these changes, a process called cardiac remodeling (14) . Cardiac fibrosis and hypertrophy are the two major processes driving cardiac remodeling.
gene expression; gene array; cardiomyocyte; fetal gene program HEART FAILURE (HF) is often the end-result of a number of cardiovascular diseases, including myocardial infarction, hypertension, and valve abnormalities. To maintain sufficient cardiac output under these conditions the heart adapts to these changes, a process called cardiac remodeling (14) . Cardiac fibrosis and hypertrophy are the two major processes driving cardiac remodeling.
The initiating stimuli for cardiac hypertrophy can be broadly separated into biomechanical or stretch-sensitive mechanisms and neurohormonal mechanisms (13) . The latter include among others catecholamines (adrenaline and noradrenaline) and endothelin-1 (ET-1), which bind to specific plasma-membrane receptors and activate intracellular signaling pathways (13) . Although these signaling pathways are inherently complex and involve significant cross talk, the common outcome, besides hormone-specific effects, is the induction of cardiomyocyte growth. This involves direct activation of protein synthesis and altered gene expression. A hallmark of cardiac hypertrophy is the activation of the so-called fetal gene program, which includes the reexpression of a number of fetal genes (29) . Important examples are atrial natriuretic peptide (ANP, NPPA) and brain natriuretic peptide (BNP, NPPB), and the latter is clinically used as an HF plasma marker (17) .
Numerous global gene expression studies have been performed on human or animal heart tissue to identify genes that are differentially expressed during HF. Usually gene expression is compared between opposing pairs, such as nonfailing vs. failing hearts, and once it is performed it is essential to narrow down the large candidate gene lists. The gene sets of different studies only partly overlap, because of diversity in disease severity, etiologies, and microarray platforms (1) . Meta-analysis of gene expression studies has therefore identified some HF genes, including ANP, BNP, ACTC1 (alpha cardiac actin), and POSTN (periostin) but also revealed that most genes were only found in a limited set of studies (1) . Gene array studies have also been performed on cultured primary neonatal rat cardiomyocytes (3, 5, 11, 16) , which are used as a general in vitro cardiomyocyte hypertrophy model. Compared with in vivo studies it has the advantage that it involves a relatively pure cell population, that there are no systemic effects present in the background, and that conditions can be well controlled. However, in vitro observations do not necessarily reflect in vivo changes. Also these studies generated large candidate lists that were not easily comparable, because of different platforms, time durations, and stimuli used (3, 5, 11, 16) .
As far as we know, no direct comparisons have been made between hypertrophy/HF-induced in vitro and in vivo gene expression changes. This combination could provide a more robust outcome and, moreover, might identify in vitro and in vivo differences. We therefore treated neonatal rat ventricular cardiomyocytes (NRVCs) with hypertrophy stimulating agents phenylephrine (PE, ␣-adrenergic), isoproterenol (Iso, ␤-adrenergic), and ET-1. In addition we used two different HF models, namely Ren2 rats that overexpress mouse renin generating hypertension and resulting in HF, and we used a rat post-MI model. Our results show overlap between the models and identified some potential novel hypertrophy/HF-associated genes. In addition interesting differences between the different models and conditions were observed.
MATERIALS AND METHODS

Reagents and chemicals.
Cell culture medium and serum were obtained from Lonza Benelux (Breda, The Netherlands), penicillinstreptomycin and trypsin were from Invitrogen (The Netherlands). Data are presented as means Ϯ SE. HF, heart failure; SD, Sprague-Dawley; MI, myocardial infarction; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; HR, heart rate; LVEDP, left ventricular end diastolic pressure; dPdtmax and dPdtmin are indexes of maximal contraction and relaxation; BW, body weight; HW, heart weight. *All values were significantly different (P Ͻ 0.05) from SD, except for HR. Fig. 1 . Confirmation of the in vivo and in vitro hypertrophy/heart failure (HF) models. A: RT-PCR on cDNA from Ren2 rats (n ϭ 5) with HF and as a control on Sprague-Dawley (SD) rats (n ϭ 4 for each group). Atrial natriuretic peptide (ANP) expression is shown relative to GAPDH levels. B: RT-PCR on cDNA from postmyocardial infarction (post-MI) HF and sham-operated rats (n ϭ 4 for each group). ANP expression is shown relative to GAPDH levels. C: primary neonatal rat cardiomyocytes were cultured for 24 h in serum-free medium and subsequently stimulated with phenylephrine (PE), isoproterenol (Iso), or endothelin-1 (ET-1). After 24 h stimulation in the presence of L- [4,5- 3 H]-leucine the radioactive incorporation in cellular protein was analyzed by liquid scintillation counting. Values are relative to the respective nontreated cultures (n ϭ 4 for each group). D: ANP expression in the different cardiomyocyte cultures was determined by RT-PCR and corrected for cyclophilin A expression (n ϭ 4). Ren2, TGRm(Ren2)27 rats; cont, control. Data are presented as means Ϯ SE. *P Ͻ 0.05 compared with control.
L- [4,5- 3 H]-Leucine (37 MBq/ml, 5,85 TBq/mmol) was from GE Healthcare Europe (Diemen, Belgium), and Ultima Gold XR scintillation liquid was from Perkin Elmer (Groningen, The Netherlands). Unless otherwise stated all chemicals were purchased at the highest possible grade from Sigma-Aldrich Chemie (Zwijndrecht, The Netherlands).
Cardiomyocyte isolation and culturing. NRVCs were isolated from the cardiac ventricles of one-to three-day-old Sprague-Dawley (SD) pups after decapitation, as previously described (22) . In short, hearts were removed from the thoracic cavity and ventricular tissue fragments were repeatedly treated with 2 mg/ml trypsin to release the cells. To remove noncardiomyocytes, isolated cells were preplated in cell culture dishes in 50 ml MEM with 5% FCS for 45 min. During this period, most noncardiomyocytes (mainly fibroblasts) attached to the dish, whereas cardiomyocytes remained in solution. The cardiomyocytes were subsequently transferred to separate tissue culture dishes and allowed to attach. NRVCs were cultured at 37°C under 5% CO 2 in DMEM and supplemented with 10% FCS and penicillinstreptomycin (100 IU/ml and 100 g/ml, respectively), as described previously (22) . For experiments in which cells were treated with hypertrophy-inducing agents, cells were first serum starved for 24 h. Cells were then treated 24 h with either 50 M PE, 10 M Iso, or 10 nM ET-1.
Animal experiments. We used male TGR(mRen2)27 (Ren2) rats that were homozygous for the expression of the mouse renin (Ren)-2 transgene (Max Delbrück Center for Molecular Medicine, BerlinBuch, Germany) (7, 18) . SD rats were used as controls. Animals were fed ad libitum. Ren2 rats and control rats were killed at 13 wk of age (30) . In parallel, HF was induced in SD rats by permanent ligation of the left coronary artery to produce a myocardial infarction (MI) (20, 32) . Anesthetic agents used: isoflurane (5% induction, 2.5% maintenance with oxygen) and proper anesthesia was confirmed by reflex analysis and by heart rate monitoring. Analgesics used: buprenorphine 0.04 mg/kg, every 8 h for 3 days. Control rats underwent a sham operation. Nine weeks later, MI animals were killed. All animals were killed under general anesthesia, as described above, by heart removal. Myocardial tissues from all groups were snap frozen for molecular analyses. From the post-MI animals remote noninfarcted cardiac tissue was used for analysis. All animal studies were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were submitted to, and approved by, the Committee for Animal Experiments of the University of Groningen.
Quantitative real-time PCR. Relative gene expression of ANP, cyclophilin-1, and GAPDH was determined by quantitative real-time PCR (RT-PCR) on a Bio-Rad CFX384 real-time system using SYBR Green dye, as described before (27) . Gene expression was determined by correcting for reference gene values (cyclophilin A or GAPDH), and the calculated values were expressed relative to the control group per experiment. Primer sequences of ANP and cyclophilin A have been described before (22) . GAPDH sequences are: GAPDH-forward, catcaagaaggtggtgaagc; GAPDH-reverse, accaccctgttgctgtag.
L- [4,5- 3 H]-Leucine incorporation assay. Cardiomyocytes were grown in 12-well plates and subsequently starved for 24 h in DMEM containing starvation medium lacking FCS. Subsequently, L- [4,5- 3 H]-leucine was added to all wells either in the presence or in the absence of 50 M PE, 10 M Iso, or 10 nM ET-1. Cells were cultured for an additional 24 h, and radioactivity incorporation was determined as described before (22) .
Microarray sample preparation and analysis. Total RNA from the cells or tissue was extracted using the Nucleospin RNA II kit (Macherey-Nagel, Düren, Germany). RNA quality was checked using the Agilent 2100 Bioanalyzer and subsequently prepared for microarray analysis using the standard Illumina TotalPrep-96 RNA Amplification Protocol (Ambion) Samples were exponentially amplified from a starting amount of 50 ng to a final amount of 1 g purified biotinlabeled cRNA using the Illumina TotalPrep-96 RNA Amplification Kit (Ambion). This final cRNA was evaluated, and the quality, concentration, and size of the reaction productions were measured using the Agilent RNA 6000 Nano Kit (Agilent). Illumina RatRef-12 Beadchips were used for microarray analysis. Chips were scanned using the BeadXpress Reader (Illumina). Beadstudio Illumina was used to import the raw data and remove any background noise. Data were converted to standard format and exported for use in Agilent Genespring GX (version 11.0, Agilent). We used Genespring to perform quantile normalization on each individual well and further analysis of the data. The MIAME standard for microarray data was followed, and all data were submitted to the CIBEX database (accession codes: CBX250 and CBX251).
Statistical analysis. All data are expressed as means Ϯ SE. The differences between two groups were determined by a Student's test. Comparisons between more than two groups of data were assessed by one-Way ANOVA followed by Bonferroni's post hoc test. For nonparametric distributed data the Mann-Whitney U-test was used. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed with Bonferroni adjustment and a minimal threshold of 3 genes. A value of P Ͻ 0.05 was considered significant.
RESULTS
In vivo rat HF models for gene expression analysis.
To identify genes that are differentially expressed during hypertrophy and HF development, we used a combined in vitro/in vivo gene array approach. For the in vivo analysis two different animal HF models were compared with their respective control groups. One group consisted of transgenic Ren2 rats (n ϭ 4), which overexpress mouse renin, resulting in hypertension and consequently HF development (7, 18) . These animals were compared with SD rats, which comprise the genetic wild-type background (n ϭ 5). In the other rat model an MI was induced by permanent ligation of the left coronary artery resulting in MI. These animals were killed 9 wk post-MI together with the sham-operated animals (n ϭ 5, 4). In the Ren2 group significant worsening of cardiac function [contraction (ϩdp/dtmax) and relaxation (Ϫdp/dtmin)] could be observed, and a similar trend was observed in the post-MI group (Table 1) . Also blood pressure dropped in the Ren2 and post-MI group. In the monogenetic Ren2 model these values were significantly different from the control, but this was not the case for the more heterogeneous post-MI model. This is related to the relative small sample size used for the gene array study, since functional parameters were significantly different in the larger group size (32) . Most importantly, with respect to gene expression, a significant increase of cardiac ANP expression, a marker for HF, was observed in both the Ren2 and post-MI groups ( Fig. 1, A and B) .
In vitro cardiomyocyte hypertrophy models. The in vitro hypertrophy model consisted of cultures of primary isolated NRVCs, which were exposed to three different hypertrophyinducing agents (n ϭ 4 in each group, PE n ϭ 3). As determined by L- [4, H]-leucine incorporation (protein synthesis), treatment with PE and ET-1 generated a strong hypertrophic response, whereas Iso induced a modest increase (Fig. 1C) . A similar trend was observed for ANP gene expression, which was strongly elevated after PE and ET-1 treatment and only modestly elevated after Iso treatment (Fig. 1D ). Together, this shows that these treatments trigger hypertrophy and fetal gene expression in cardiomyocytes in vitro.
Gene array analysis animal models. Whole genome gene expression in the cardiac animal samples and of the cardiomyocyte cultures was analyzed using Illumina RatRef-12 Beadchip arrays. Only those genes that showed a significant 1.5-fold change in gene expression (P Ͻ 0.05) compared with their respective control groups were selected. This yielded 159 differentially expressed genes in the Ren2 group and 254 differentially expressed genes in the MI group. Subsequently, the overlap in both HF groups was analyzed, yielding only a small set of 58 genes (16%) that were similarly up-or downregulated in both groups ( Fig. 2A) . Since genes that are just above selection threshold in one group might be missed in the other group this representation could give a biased view. Therefore, we also analyzed whether the top 10 up-and downregulated genes in the Ren2 and MI groups showed a similar distribution. As can be seen from Table 2 , this is indeed the case. Within this top 10, several common HF markers, including POSTN (26) and ANP (17) , were similarly upregulated in both animal groups. It is remarkable, however, that the strongest upregulated gene in the Ren2 group, KCNE1 (potassium channel, voltage-gated, ISK-related subfamily, member 1) was not upregulated in the MI group. This was also true for RGD1562305 (SBSN, suprabasin), although the latter did show a significant increase in the post-MI model by RT-PCR, albeit much smaller than in the Ren2 rats (see below and Fig. 3 ). In the MI group CA3 (carbonic anhydrase 3) was strongly upregulated, but this could not be confirmed by RT-PCR (see below and Fig. 3 ). The full gene tables are presented in Supplemental Data List 1.
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In vitro cardiomyocyte hypertrophy models. Whole genome gene expression of the hypertrophy-induced cardiomyocyte cultures was compared with the untreated culture group. This revealed that 415, 170, and 321 genes were differentially expressed after PE, ET-1, and Iso treatment respectively (P Ͻ 0.05, Ͼ1.5-fold difference) (Fig. 2B) . Thus both adrenergic stimuli (PE and Iso) gave a stronger hypertrophic effect than ET-1, even though hypertrophy development with Iso was less pronounced compared with ET-1 (Fig. 1C) . Comparison of these data sets showed a common overlap of 71 genes. A list of the 10 most upregulated genes present in at least two conditions is presented in Table 3 . Most of the top 10 genes were upregulated by all three stimuli and include known cardiac disease genes, like Xirp2, Scn3b, and ACTC1. Although HF markers, like ANP and BNP, were not present in this top these are present in the full gene list (Supplemental Data List 2). It is remarkable that the strongest upregulated gene, PNOC (prepronociceptin), was specific for PE and Iso stimulation. In addition, the potassium voltage-gated channel KCND2 was upregulated only in ET-1-treated cells, and the aldo-keto reductase gene AKR1B8 was specific for Iso stimulation. Most downregulated genes were specific for adrenergic stimulation (Iso and/or PE), including the strongly downregulated short chain dehydrogenase/reductase gene Dhrs7c. Only one gene of the top 10 genes was downregulated by all three stimuli, ANGPT2 (angiopoietin 2), a protein involved in vascular remodeling (9) .
Comparison of the in vitro and in vivo data sets. To compare the in vitro data with the in vivo data all differentially in vitro expressed genes that were present in at least two conditions (253 genes) were compared with all differentially in vivo expressed genes (355 genes). This yielded a set of 62 genes differentially expressed in at least two in vitro and one in vivo model (Fig. 2C) . Within the group of 62 genes, established hypertrophy/HF markers like ANP and BNP and a promising new HF marker LGALS3 (galectin-3) were present (6, 8) . Based on the average fold change gene expression we made a list of the top 10 up-and downregulated genes found in at least two in vitro models and one in vivo model (Table 4) . In this list, a number of known HF markers and cardiac disease genes are present, like ANP, XIRP2, CSRP2, FHL1, TIMP1, and LGALS3. However, it also includes novel upregulated genes like AKIP1 (also termed BCA3 or C11Orf17), PTGIS, and downregulated genes, like DHRS7c (Table 4) . We also identified a large number of genes that showed differential expression in vitro, but not in vivo and vice versa (Table 5 and Supplemental Data List 3).
Confirmation of gene expression changes. To confirm our gene array data we performed gene expression analysis by quantitative real-time PCR of a selected number of identified genes in post-MI and Ren2 rats. First, we analyzed expression of Xirp2 and PTGIS, which were upregulated both in in vitro and in vivo models (Table 4) . Like ANP, PTGIS was significantly upregulated in post-MI rats and, albeit just not significant, also in Ren2 animals, whereas Xirp2 was significantly 1 The online version of this article contains supplemental material. IDENTIFICATION OF HEART FAILURE-ASSOCIATED GENES upregulated in the Ren2 model only (Fig. 3, A-D) . In vitro, both genes were clearly upregulated with adrenergic stimulation and to a lesser extent also with ET-1 (Fig. 4, A and B) . These data are largely in concert with the gene array data. We also analyzed some genes that were only upregulated in the in vivo models. As shown in Fig. 3 , E and F, POSTN was significantly upregulated in both models, and KCNE1 was strongly upregulated only in the Ren2 model, in accordance with the gene array data. SBSN, was strongly upregulated in the gene array in Ren2 animals, and this could be reproduced by RT-PCR (Fig. 3I) . However, it also revealed a much smaller, but significant upregulation in MI animals (Fig. 3J) , which was missed in the gene array. CA3, on the other hand, was, according to the gene array data, highly upregulated in the MI model, but this could not be confirmed by the RT-PCR. A large variation in CA3 expression between the animals was observed, and the small sample size used in the gene array may explain why it was accidently picked up. POSTN and SBSN were not regulated in vitro by hypertrophic stimuli (Fig. 4 , C and E), in agreement with the gene array data. We also tested expression of PNOC, a gene that was strongly induced by adrenergic stimulation in vitro. We could confirm this observation by RT-PCR (Fig. 4F) and also tested expression of PNOC in our animal models but could not detect any expression of this gene. We therefore decided to compare the expression of the above-mentioned genes in neonatal and adult hearts, No value given indicates absence of significant up-or downregulation. Control, n ϭ 4; endothelin-1 (ET-1), n ϭ 4; isoproterenol (Iso), n ϭ 4; phenylephrine (PE), n ϭ 3. to see whether additional baseline differences were present between neonatal and adult heart tissue. As shown in Fig. 5 , A-F, the expression of PTGIS, POSTN, KCNE1, SBSN, and PNOC was all significantly higher in neonatal tissue compared with adult tissue. The only exception was Xirp2, which was higher in adult tissue, albeit not significantly. Finally, we also tested expression of several genes (including LOXL1 and NUPR1) in cultured neonatal cardiac fibroblasts treated with PE, Iso, and ET-1. Except for POSTN and SBSN, which showed some increased expression after PE treatment, no changes were observed in these fibroblasts (data not shown). This confirms that all changes we observed in our in vitro system were cardiomyocyte specific. Of course it does not exclude that in neonatal cardiac fibroblasts these genes may be regulated by other stimuli. GO analysis. Finally, we performed GO on the different data sets using Genetrail and complemented this with KEGG pathway analysis. Both Tables 6 (GO analysis) and 7 (KEGG pathways) show that there are strong differences between the in vitro data sets on one hand and the in vivo data sets on the other hand. Full data sets can be found in Supplemental Data Lists 4 and 5. GO analysis revealed significant induction of genes involved in sterol and cholesterol metabolism in vitro, but not in the in vivo models (Table 6 ). Also myofibril and contractile fiber groups were upregulated in the in vitro, but not in vivo data sets. Oxidoreductase activity-encoding genes were only upregulated in the Iso-treated cells. In the in vivo data sets the extracellular proteins, in particular matrix-encoding genes like LTBP, POSTN, fibronectin (FN1), and LOXL1, were highly upregulated. In addition in the in vivo models, mitochondrial proteins were downregulated, indicative for changes in metabolism in vivo. Surprisingly, only in the MI model fatty acid and lipid oxidation were downregulated at the gene expression level. Similar results were obtained in the KEGG pathway analysis, which clusters genes to specific pathways (Table 7) . Again steroid and terpenoid biosynthesis pathways were strongly upregulated in vitro. Especially in PE-and ET-1-treated cells, nearly all genes of these pathways, which together are involved in sterol, cholesterol, and steroid biosynthesis, were upregulated (Fig. 6) . In Iso-treated cells glutathione metabolism was upregulated, again pointing toward oxidative stress. In vivo, signaling proteins interacting with the extracellular matrix were upregulated. Metabolic genes were downregulated in the in vivo models and fatty acid metabolism only in the MI model.
DISCUSSION
Cardiomyocyte growth (hypertrophy) is one of the hallmarks of HF development (13, 14) . Here we investigated gene expression profiles of in vitro cultured cardiomyocytes treated with hypertrophy-inducing agents (PE, ET-1, and Iso) and in vivo HF models (hypertensive Ren2 rats and post-MI rats). This approach yielded large data sets of differentially expressed genes. By overlapping them we obtained a concise set of genes, including numerous known HF markers. Interestingly, this set also included a number of interesting genes not linked to hypertrophy/HF before and revealed striking difference between in vitro and in vivo models.
Analysis of differential gene expression in cardiomyocytes stimulated with hypertrophy-inducing agents and in two rat HF models generated large lists of differentially expressed genes. By combining these expression data sets we obtained a concise list of 62 differentially expressed genes. This list included most known HF markers, including ANP, BNP, TIMP1, FHL1, SGAL3 (Table 4 and Supplementary Data List 3), indicating that this is a powerful approach to identify differentially expressed genes that are linked to hypertrophy and HF development. This list also comprised genes that have recently been linked to cardiac remodeling, like TNFRSF12a (also termed Fn14) (4), indicating that this approach could uncover new HF genes. In fact this list contained a number of genes that have All listed genes with (Ͼ1.5-fold change and P Ͻ 0.05). 
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IDENTIFICATION OF HEART FAILURE-ASSOCIATED GENES previously not been linked to hypertrophy and HF development. This list includes PTGIS (also termed PGIS, CYP8), a gene for which MI, hypertension, and stroke-associated polymorphisms have been identified by genome-wide association studies (25) . PTGIS encodes a prostacyclin synthase and is a key enzyme in the synthesis of prostacyclin (PGI2), which is an inhibitor of platelet aggregation and a short-acting vasodilator and can contribute to the development of stroke, MI, and atherosclerosis (15) . Moreover, mouse PGI2 receptor knockout mice develop cardiac hypertrophy and fibrosis (10) . Other interesting genes include AKIP1, an adaptor protein in the PKA-NFB pathways (12, 31) , and the short chain dehydrogenase/reductase Dhrs7c, which is downregulated in most models. This downregulation of Dhrs7c has in the meantime also been confirmed in cardiac biopsies from HF patients, also at the protein level (23) . Our inventory could therefore be an important starting point for the investigation of novel genes associated with HF. Our investigations also revealed clear differences between in vitro and in vivo experiments (Tables 5-7) . GO and KEGG pathway analysis revealed a strong enrichment of genes involved in the steroid biosynthetic pathway that are specifically upregulated in vitro after hypertrophic stimulation, but not in vivo. Since these pathways are essential for the novo cholesterol synthesis, it might suggest that there is an increased requirement for cholesterol during hypertrophic growth of cardiomyocytes. In the in vivo models a strong enrichment for extracellular matrix and stress-specific genes was observed. Only pathways that were at least identified in one model with a P value Ͻ1.0 e Ϫ3 are shown.
This included the highly expressed genes LTBP, POSTN, FN1, and LOXL1, which are predominantly expressed by fibroblasts or other noncardiomyocytes in the heart and explains the absence in the in vitro cardiomyocyte experiments. The in vivo-specific list may therefore contain differentially expressed HF genes that are specific for noncardiomyocytes, and novel genes within this list, like MGC72614 (FAM198B), may therefore be linked to fibrotic or stress-related processes. Also within the in vitro and in vivo models striking differences were observed. In vitro, for example oxidative stress appeared to be increased after Iso treatment as extrapolated from the increased expression of oxidoreductase and glutathione metabolic genes. This is in line with papers describing activation of oxidative stress pathways in cardiomyocytes after beta adrenergic stimulation (reviewed in Ref. 28 ). In our post-MI model, genes related to the wounding response were upregulated, but not in our Ren2 model; this is most likely related to the severe myocardial damage in the MI model. Fatty acid metabolic genes were downregulated in the post-MI model, in line with the substrate shift from fatty acids to glucose that occurs during HF development (21) (19) . Surprisingly, however, this change was not observed in our monogenetic Ren2 rat model, with hypertension, which had at least the same extent of hypertrophy/HF development. This suggests that this substrate shift is not obligatorily linked to hypertrophy development but might be associated with the respective different etiologies that contribute to HF development.
We performed RT-PCR on a selected set of genes identified in the array and could confirm differential expression of most genes. Only CA3, which appeared to be highly upregulated in the MI model, could not be replicated and showed similar, but highly variable expression in all groups. On the other hand we could confirm the specific upregulation of KCNE1 in the Ren2 model. This might be indicative for etiologic differences, although we cannot exclude the possibility that it is dependent on the severity of the disease. SBSN (RGD1562305) expression was strongly increased in the Ren2 group, and also an increase in the MI group could be observed. This gene was not upregulated in cardiomyocytes after hypertrophy stimulation in vitro but did show some increased expression in PE-treated fibroblasts, suggesting that it might be more fibroblast related. This extracellular protein was originally suggested to play a role in striated epithelia (24) but was recently also shown to be strongly induced in muscle of exercised dogs (2) . Together with our observation, this may suggest that SBSN also plays a role in heart and muscle function under stress-related conditions. It might therefore be rewarding to investigate plasma levels of this secreted protein in HF patients.
Several features of the experiments are important in the interpretation of the present data. First we used neonatal rat cardiomyocytes for in vitro hypertrophy and compared these data with in vivo adult rat HF models. Therefore some of the differences between the in vitro and in vivo data could be related to the age of the cells, neonatal vs. adult. Indeed we could observe baseline differences between neonatal and adult hearts, and PNOC expression, for example, was absent in adult tissue. We made the choice for neonatal rat cardiomyocytes, because these cells are used as an established model for in vitro cardiomyocyte hypertrophy. Our results show, however, some important differences between this in vitro model and the in vivo situation. Some differences could be related to the timing of the experiments. In vitro hypertrophy induction only lasted 24 h, and therefore some of the changes might be related to early responses in contrast to the in vivo experiments. Some of the effects might also be temporal or related to the severity of HF and hence be present in one, but not the other group. As with most screens we also missed some known HF-associated genes, like SERCA2a, indicating that although comprehensive the generated lists are not complete.
In conclusion, we have identified a comprehensive set of genes that are differentially expressed in in vitro cardiomyocyte models for hypertrophy and in animal HF models. This list includes a large number of genes known to be associated with HF, as well as potential new targets, like AKIP1, for future analysis. Furthermore, we have identified a large number of genes that appear to be specific for particular conditions. This stresses again that we have to be careful with extrapolations from one to another model or condition. These datasets should prove invaluable for a further analysis of cardiac diseases in particular pathological hypertrophy and HF development.
ACKNOWLEDGMENTS
We thank Bahram Sanjabi, who performed the gene array hybridization and detection at the Department of Genetics, University Medical Center Groningen, The Netherlands. 
